Provenge, Jevtana Covered Without PA By Nearly 50% Of Payers In Analysis
Executive Summary
Dendreon’s Provenge (sipuleucel-T) and Sanofi-Aventis’ Jevtana (cabazitaxel) were covered by nearly 50% of commercial plans without prior authorization requirements during the first quarter of 2011, according to an analysis of payer policies for the novel prostate cancer therapies conducted by The Zitter Group.
You may also be interested in...
NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis
The U.K.'s cost regulator, NICE, rejects Sanofi's lauded prostate cancer therapy cabazitaxel because it considers it too expensive.
Medicare Provenge Decision Addresses Treatment Eligibility Criteria
The final national coverage decision confirms that Provenge will be covered for its labeled uses and that off-label use will be left to the discretion of local administrative claims contractors.
Provenge Medicare NCD Needs More Clarity To Avoid Restrictions, CMS Told
Medicare’s final national coverage decision on Dendreon’s prostate cancer vaccine Provenge (sipuleucel-T) should more clearly lay out how far local Medicare claims contractors can go in ensuring patients are eligible for treatment, comments from the manufacturer, oncology care providers and physicians say.